Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development

Journal of Public Economics

Volumn 97, Issue 1, 2013, Pages 327-336

  Blume Kohout, Margaret E ^a   Sood, Neeraj ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Innovation; Medicare Part D; Pharmaceutical industry; Research and development

Indexed keywords

EID: 84871908621     PISSN: 00472727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpubeco.2012.10.003     Document Type: Article

References (30)

1. Abrantes-Metz R.M., Adams C.P., Metz A.D. Pharmaceutical development phases: a duration analysis. Journal of Pharmaceutical Finance, Economics and Policy 2005, 14:19-41.
2. Acemoglu D., Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics 2004, 119:1049-1090.
3. Adams C.P., Brantner V.V. Estimating the cost of new drug development: is it really $802 million?. Health Affairs 2006, 25:420-428.
4. Arrowsmith J. Phase II failures: 2008-2010. Nature Reviews. Drug Discovery 2011, 10:1-1.
5. Blume-Kohout M.E. Does targeted, disease-specific public research funding influence pharmaceutical innovation?. Journal of Policy Analysis and Management 2012, 10.1002/pam.21640.
6. Civan A., Maloney M.T. Determinants of pharmaceutical research and development investments. The B.E. Journal of Economic Analysis & Policy 2006, 5:1-36.
7. DiMasi J. New drug development in the United States from 1963 to 1999. Clinical Pharmacology and Therapeutics 2001, 69:286-296.
8. Dubois P., de Mouzon O., Scott-Morton F., Seabright P. Market size and Pharmaceutical Innovation. Institut d'Economie Industrielle Working Paper 2011, Institut d'Economie Industrielle, University of Toulouse, Toulouse, France.
9. Duggan M., Scott Morton F. The effect of Medicare Part D on pharmaceutical prices and utilization. The American Economic Review 2010, 100:590-607.
10. Duggan M., Healy P., Scott Morton F. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D. The Journal of Economic Perspectives 2008, 22:69-92.
11. Finkelstein A. Static and dynamic effects of health policy: evidence from the vaccine industry. Quarterly Journal of Economics 2004, 119:527-564.
12. Friedman J.N. The Incidence of the Medicare Prescription Drug Benefit: Using Asset Prices to Assess its Impact on Drug Makers. Harvard University, Job Market Paper 2009.
13. Giaccotto C., Santerre R.E., Vernon J.A. Drug prices and research and development investment behavior in the pharmaceutical industry. Journal of Law and Economics 2005, 48:195-214.
14. Gitterman D.P., Greenwood R.S., Kocis K.C., Mayes B.R., McKethan A.N. Did a rising tide lift all boats? The NIH budget and pediatric research portfolio. Health Affairs 2004, 23:113-124.
15. Golec J., Hegde S., Vernon J.A. Pharmaceutical R&D spending and threats of price regulation. Journal of Financial & Quantitative Analysis 2010, 45:239-264.
16. Grabowski H.G., Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Managerial and Decision Economics 2007, 28:491-502.
17. Holmer A.F. Covering prescription drugs under Medicare: For the good of the patients. Health Affairs 1999, 18:23.
18. IMS Institute for Healthcare Informatics The Global Use of Medicines: Outlook through 2016 2012, IMS Health, Parsippany, NJ: IMS Health, Available online at: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf.
19. Ketcham J.D., Simon K. Medicare Part D's Effects on Elderly Drug Costs and Utilization. National Bureau of Economic Research, Inc., NBER Working Papers: 14326 2008.
20. Lakdawalla D., Sood N. Incentives to Innovate. The Oxford Handbook of the Economics of the Biopharmaceutical Industry 2012, 143-166. Oxford University Press, New York. P.M. Danzon, S. Nicholson (Eds.).
21. Lichtenberg F.R., Sun S.X. The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs 2007, 26:1735-1744.
22. Medicare Payment Advisory Commission Report to the Congress: Variation and Innovation in Medicare 2003, MedPAC, Washington, DC.
23. Oliver T.R., Lee P.R., Lipton H.L. A political history of Medicare and prescription drug coverage. The Milbank Quarterly 2004, 82:283-354.
24. Scherer F.M. The link between gross profitability and pharmaceutical R&D spending. Health affairs (Project Hope) 2001, 20.
25. Shea A.M., Curtis L.H., Hammill B.G., DiMartino L.D., Abernethy A.P., Schulman K.A. Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. JAMA: The Journal of the American Medical Association 2008, 300:189-196.
26. Sood N., de Vries H., Gutierrez I., Lakdawalla D.N., Goldman D.P. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Affairs 2009, 28:W125-W137.
27. Verdier J., Bagchi A., Esposito D. Medicaid prescription drug use by dual eligibles: issues for Medicare Part D 2008, Mathematica Policy Research, Princeton, NJ.
28. Vernon J.A. Pharmaceutical R&D investment and cash flows: an instrumental variables approach to testing for capital market imperfections. Journal of Pharmaceutical Finance, Economics, & Policy 2005, 13:3-17.
29. Yin W. Market incentives and pharmaceutical innovation. Journal of Health Economics 2008, 27:1060-1077.
30. Yin W., Basu A., Zhang J.X., Rabbani A., Meltzer D.O., Alexander G.C. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine 2008, 148:169-177.